Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug 24;22(1):313.
doi: 10.1186/s12883-022-02837-5.

Relapsing MRI-negative myelitis associated with myelin-oligodendrocyte glycoprotein autoantibodies: a case report

Jan Kolcava  1   2 , Aneta Rajdova  3   4   5 , Eva Vlckova  3   4   5 , Pavel Stourac  3   4 , Josef Bednarik  3   4   5
Affiliations
Case Reports

Relapsing MRI-negative myelitis associated with myelin-oligodendrocyte glycoprotein autoantibodies: a case report

Jan Kolcava et al. BMC Neurol. .

Abstract

Background: Serum antibodies to myelin-oligodendrocyte glycoprotein (MOG) are biomarkers of MOG-IgG-associated disorder (MOGAD), a demyelinating disease distinct from both multiple sclerosis and aquaporin-4-IgG neuromyelitis optica spectrum disorder. The phenotype of MOGAD is broad and includes optic neuritis, transverse myelitis, and acute demyelinating encephalomyelitis. Myelitis is common with MOGAD and typically results in acute and severe disability, although prospects for recovery are often favorable with prompt immunotherapy.

Case presentation: This contribution presents a unique case report of a young male patient exhibiting relapsing myelitis with normal spinal cord and brain magnetic resonance imaging. Comprehensive diagnostic assessment revealed myelin-oligodendrocyte glycoprotein-IgG-associated disorder.

Conclusion: MOGAD is one of the conditions which should be considered in MRI-negative myelitis. The diagnosis, however, may prove difficult, especially if the patient is not exhibiting other neurological symptoms of MOGAD. Conus or epiconus involvement is common in MOGAD; the patient reported herein exhibited incomplete rostral epiconus symptoms which, together with somatosensory evoked potential abnormalities, led to the diagnosis.

Keywords: Case report; Demyelinating diseases; Evoked potentials; Magnetic resonance imaging; Myelin-oligodendrocyte glycoprotein.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Figures

Fig. 1
Fig. 1
Magnetic resonance imaging scan of the brain and cervical, thoracic and lumbar spine (SIGNA Voyager 1.5T)
Fig. 2
Fig. 2
Somatosensory-evoked potentials established a central lesion of the spinal somatosensory pathway to the lower extremities
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Banks SA, Morris PP, Chen JJ, Pittock SJ, Sechi E, Kunchok A, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. 2021;92:348–8. doi: 10.1136/jnnp-2020-325121. - DOI - PMC - PubMed
    1. Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76:301–9. doi: 10.1001/jamaneurol.2018.4053. - DOI - PMC - PubMed
    1. Clerici AM, Nobile-Orazio E, Mauri M, Squellati FS, Bono GG. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy. BMC Neurol. 2017;17:127. doi: 10.1186/s12883-017-0906-2. - DOI - PMC - PubMed
    1. Van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17:356–63. doi: 10.1111/j.1468-1331.2009.02930.x. - DOI - PubMed
    1. Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267:3565–77. doi: 10.1007/s00415-020-10026-y. - DOI - PMC - PubMed

Publication types

LinkOut - more resources